any one of the many components of a biological process causes related changes to molecular characteristics and functions of the cell: the observable composite of which is the cellular phenotype. Observing how and when cellular phenotypes are altered by specific stressors can provide clues about underlying mechanisms of disease while facilitating the identification of new therapeutic targets.
LINCS data are made openly available as a community resource through a series of data releases to enable scientists to address a broad range of basic research questions. Results are obtained in cultured and primary cells whose state has been perturbed experimentally, with the term ''perturbagen'' used to refer to any condition that can alter the cellular state. LINCS datasets therefore consist of assay results from cells treated with bioactive small molecules, antibodies, and ligands, such as growth factors and cytokines, microenvironment proteins, genetic perturbations, and comparisons of disease versus normal primary cells from patients and healthy control subjects. Many different assays are used to measure cell responses, including measurements of mRNA and protein expression; epigenomic status; and cellular, molecular, and morphological phenotypes captured by biochemical and imaging readouts (Figures 1 and 2) . Assays typically are carried out on multiple cell types at multiple time points, and perturbagens are applied at multiple doses. The LINCS program has been implemented in two phases. The pilot phase of the program was completed in 2013 and was focused on initial production of perturbationinduced molecular and cellular signatures, assay development, development of data standards, as well as tools and databases for accessing the data. Phase 2, which began in 2014, and is the focus of this Perspective, supports six LINCS Data and Signature Generation Centers (DSGCs) and one Data Coordination and Integration Center (DCIC). The data coordination center synergizes LINCS-related activities with the NIH Big Data to Knowledge (BD2K) program (Margolis et al., 2014) . The focus in phase 2 remains on the large-scale production of perturbation-induced molecular and cellular signatures, as well as computational tool development, integrative data analyses, integration of external public datasets with data generated by LINCS, metadata annotation that strictly follows the Findable, Accessible, Interoperable, and Reusable (FAIR) guidelines (Wilkinson et al., 2016) , and outreach activities to engage the next generation of biomedical data scientists and promote the LINCS Consortium. A summary of the LINCS program by the numbers is provided in Figure 1 . Box 1 contains web URLs to major LINCS program and project websites. To aid the reader, abbreviations used in this Perspective may be found in Box 2.
While there are many published works using LINCS data, particularly the L1000 small-molecule perturbation dataset (Fallahi-Sichani et al., 2017; Iwata et al., 2017; Mirza et al., 2017; Wang et al., 2016b) , a review of the transcriptomic efforts of the LINCS program in the context of connectivity map (CMAP) (Musa et al., 2017) , and specifications for LINCS metadata (Vempati et al., 2014) , there is no comprehensive description of the LINCS program in the literature to date. Given the pre-publication availability of many of the LINCS datasets, with associated tools designed to make the data accessible to both computational and experimental researchers, LINCS resources as a whole represent a tremendous community asset for scientists from a variety of disciplines. This Perspective is targeted toward computational systems biologists from academia, pharma, and biotech who could use LINCS resources to enrich their own research programs given the wide-ranging applicability of LINCS program resources. Readers of this article should come away with a better understanding of what the NIH LINCS program encompasses, the LINCS program vision, what datasets are available, and where to access them, how these datasets were generated, including the novel technologies developed as part of the LINCS program, and the tools available to aid in the analysis of these datasets.
The LINCS DSGCs
The LINCS Consortium supports six DSGCs and the BD2K-LINCS DCIC. Below we provide a summary of the DSGCs. Each center has distinct experimental approaches and strategies, which, taken together, provide multiple, complementary facets of molecular perturbations. The Drug Toxicity Signature LINCS Center The Drug Toxicity Signature (DToxS) Generation LINCS Center at the Icahn School of Medicine at Mount Sinai in New York aims to generate cellular signatures that predict adverse effects of Food and Drug Administration (FDA)-approved drugs, particularly cardiotoxicity, hepatotoxicity, and peripheral neuropathy. These signatures may also be used to predict how co-administration of drug pairs may either exacerbate or mitigate adverse effects. Drugs and drug pairs are selected as perturbagens based on adverse events reporting of commonly used FDA-approved drugs. The initial efforts of DToxS are focused on cardiotoxicity caused by cancer therapeutics, particularly heart failure and reduced ventricular function resulting from treatment with kinase inhibitors. The center uses genomic and high-throughput proteomic measurements (with proteomics experiments being conducted at the Center for Advanced Proteomics at Rutgers New Jersey Medical School) and medium-throughput experimental measurements of perturbagen-induced changes in protein state. Multiple levels of data analysis are performed, including: (1) correlating expression changes with clinical risk scores; (2) identifying common protein structural motifs; (3) predicting the biological processes involved in toxicity through network analysis; and (4) developing mechanistic understanding by integrating data with models that describe dynamics. The different levels of analysis can help to identify signatures for both toxicity and toxicity mitigation. DToxS Unique Featured Assay: Microwestern Array. The microwestern array is a scalable miniaturization of a western blot, performing either 24, 48, or 96 traditional western blots at a time. It is employed for measuring protein levels and post-translational modifications in a medium-throughput format that allows for multiple conditions to be tested in parallel (Ciaccio and Jones, 2017) . Similar to the reverse-phase protein array (RPPA) (Tibes et al., 2006) , in which whole-cell lysates are applied to nitrocellulose slides, probed with antibodies, and measured via a chemiluminescent reporter, the microwestern has the additional step of electrophoretic protein separation by molecular weight. In brief, cell lysates are spotted onto an acrylamide gel, subjected to electrophoresis, transferred to nitrocellulose, blotted with antibodies in a gasket apparatus to isolate samples, and then imaged and quantified via infrared fluorescent secondary antibodies. The Harvard Medical School LINCS Center The Harvard Medical School (HMS) LINCS Center uses multiple measurement methods to collect data and compute signatures from cells exposed to small-molecule drugs and naturally occurring ligands. The Center emphasizes integration of imaging, mass spectrometry, and transcript profiling approaches, and collects both single-cell and population-average data. The Center also develops data analysis pipelines and informatics systems, which are particularly important in the case of microscopy data for which few such systems exist. The research products of the HMS Center comprise new measurement technologies, multi-dimensional datasets, and open source software.
The HMS Center focuses on kinase inhibitors and epigenomemodifying compounds as perturbagens because they are prototypical of drugs that aim for selective targeting of members of multi-gene families. The great majority of such drugs are active against several targets, and a key goal of the HMS Center is to characterize such poly-selectivity and understand the therapeutic implications. The majority of data in the HMS Center is collected from transformed cell lines, in part because they are simple to grow in large numbers; however human primary cells (e.g., fibroblasts for example) and iPSC-derived, trans-differentiated cells (e.g., cardiomyocytes) are also studied. Signatures and tools developed by the HMS Center are designed to help others analyze drug and ligand dose-response relationships, biomarkers of drug resistance, and the origins and consequences of cell-to-cell variability. Signatures and systematic (Lin et al., 2015 (Lin et al., , 2016 , making it well-suited to high-throughput characterization of perturbagen response. CycIF data can be analyzed using computational algorithms developed for other multiplex singe-cell methods, cytometry by time of flight mass spectrometry for example.
The LINCS Center for Transcriptomics
The Broad Institute's LINCS Center for Transcriptomics and the CMAP team aims to develop a comprehensive resource of cellular state expression signatures spanning millions of genetic and small-molecule perturbations. Genetic perturbations include CRISPR knockout, small hairpin RNA knockdown, and open reading frame overexpression. Each genetic or smallmolecule perturbation readout includes approximately 1,000 genes and uses the L1000 assay, a high-throughput, low-cost gene expression profiling platform. These data are publicly available via databases and applications with attention to features that enable meaningful user interaction with the data to foster biological discovery. The CMAP team catalogs the connections between these gene expression signatures to find drugs, diseases, pathways, and targets (Lamb et al., 2006 based detection on 384-well plates (Subramanian et al., 2017) . Given the highly correlated structure of gene expression, the non-measured transcriptome can be computationally inferred from these landmark genes, which were selected to enable faithful reconstruction using an algorithm trained on a large set of complete transcriptomes. In addition, 80 invariant genes are measured to allow for scaling and normalization. The method has been shown to be comparable with RNA sequencing (RNA-seq) at a fraction of the cost and has produced a compendium of over a million publicly available cellular perturbation profiles.
The LINCS Proteomic Characterization Center for Signaling and Epigenetics at the Broad Institute
The Broad Institute's LINCS Proteomic Characterization Center for Signaling and Epigenetics (PCCSE) seeks to understand how changes in cellular signaling, transcriptional, and epigenetic states influence one another via feedforward and feedback processes. Perturbations to these states are induced by drug treatments or genetic manipulations (via CRISPR) of cancer cell models, neuronal lineages, or primary vascular cells. The PCCSE uses mass spectrometry-based targeted proteomics to assay cellular phosphosignaling and histone modification responses elicited by these perturbations. Given the strong focus on signaling and epigenetics, the drug and genetic perturbations being selected include a number of kinase inhibitors, epigenetically active drugs, and knockdowns of core chromatin modifying genes. These experiments, coupled with matched L1000 data obtained via collaboration with the LINCS Center for Transcriptomics, are designed to test the hypothesis that early cell signaling responses to perturbation may establish new cellular states by altering epigenetic landscapes. LINCS PCCSE Unique Featured Assays: P100 and GCP Proteomics. The LINCS PCCSE employs two unique targeted proteomics assays: the P100 and global chromatin profiling (GCP) proteomics platforms. P100 measures the level of 96 phosphopeptides that are commonly observed and modulated in diverse cell types (Abelin et al., 2016) , and serves as a ''sentinel assay'' for the phosphosignaling state of the cell (Soste et al., 2014) . By comparing P100 profiles of uncharacterized perturbations with those induced by drugs known to inhibit distinct signaling pathways, this method can infer specific alterations in cellular signaling states. GCP is a similar targeted mass spectrometry-based assay that profiles global histone post-translational modifications in bulk chromatin (Gopal et al., 2016) . The probes that monitor combinations of post-translational histone modifications serve to generate epigenetic signatures of genetic or small-molecule disruption of the epigenetic machinery. Data from both assays are compatible with the CMAP framework developed by the LINCS Center for Transcriptomics to interrogate and integrate large-scale datasets.
The Microenvironment Perturbagen LINCS Center
The Microenvironment Perturbagen (MEP) LINCS Center aims to generate datasets and computational strategies to illuminate how combinatorial signals from the microenvironment (ME) affect intracellular molecular networks and their resultant cellular phenotypes. This is accomplished by profiling cells after treatment with select soluble and insoluble proteins (extracellular matrix proteins, growth factors, and cytokines) identified to be variably enriched in primary tissues. The MEP LINCS Center studies both transformed cell lines as well as normal human primary cells to learn how cell phenotypes change in response to growth with >2,500 different microenvironmental perturbagen combinations. Regulatory relationships are inferred by extracting quantitative ME response phenotype features through multi-color imaging of biomarkers associated with specific cellular phenotypes, measurement of protein expression using RPPA (Tibes et al., 2006) , and measurement of gene transcription using the L1000 platform (Subramanian et al., 2017) . The development of analytical pipelines and data management systems for largescale, high-content imaging data is a key component of the MEP LINCS Center, and this effort is coordinated with the HMS LINCS and NeuroLINCS Centers, both of which have large imaging components. Examples of the use of MEP LINCS data include identification of microenvironmental perturbagens that elicit specific phenotypes, understanding how microenvironmental signals modulate response to therapy, and identification of cellular networks associated with particular cellular phenotypes. MEP LINCS Unique Featured Assay: MEMA Platform. The MEP LINCS Center has developed a microenvironment microarray (MEMA) platform to systematically interrogate ME effects on cellular phenotypes (Lin et al., 2012; Watson et al., 2014) . MEMA consists of thousands of unique combinations of soluble and insoluble ME-associated proteins. Insoluble proteins are printed on a solid substrate to form pads upon which cells can be grown while soluble factors are added to the culture medium within each well of a multi-well plate, yielding thousands of unique combinations of MEPs. MEMA includes factors that are secreted by multiple different cell types, including macrophages, infiltrating lymphocytes, stromal fibroblasts, and vascular endothelial cells, although the platform could be customized to assess nearly any soluble or insoluble protein. Following incubation, cells are fixed, stained for endpoints targeting morphology, metabolism, cell cycle, nuclear activity, and differentiation status, and subjected to high-content imaging.
The NeuroLINCS Center
The NeuroLINCS Center currently studies the motor neuron diseases amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) by characterizing the molecular networks within patient-derived induced pluripotent stem cells (iPSCs) and their differentiated motor neuron progeny. However, it is expanding to develop a global cortical neuron assay from iPSCs that will be of interest to groups working in other neurodegenerative diseases such as Alzheimer's disease. Assays used include highthroughput imaging, RNA-seq, ATAC-seq, and SWATH mass spectrometry to inspect differences in the cellular physiological, transcriptomic, epigenetic, and proteomic landscapes, respectively, of ALS and SMA patient neurons compared with unaffected controls. Perturbations include ALS-and SMA-relevant mutations in patient-derived iPSCs as well as additional chemical perturbations. NeuroLINCS is a collaborative effort between multiple research groups at University of California, Irvine, Cedars-Sinai Medical Center, the Gladstone Institute, MIT, and Johns Hopkins University. It combines expertise in iPSC technology, disease modeling, transcriptomics, epigenomics, metabolomics, proteomics, whole-genome sequencing, cell-based assays, bioinformatics, statistics, and computational biology. A unique feature of NeuroLINCS is the bioinformatics integration of the diverse high-throughput ''omic'' datasets to provide a network-based understanding of underlying pathways. In addition, the NeuroLINCS Center is collaborating with Google to integrate signatures across platforms into highly predictive models of responses to perturbagens using machine learning. The BD2K-LINCS DCIC The BD2K DCIC for LINCS consists of four major components: Integrated Knowledge Environment (IKE), Data Science Research (DSR), Community Training and Outreach (CTO), and Consortium Coordination and Administration. The IKE is enabling federated access, intuitive querying, and integrative analysis and visualization across all LINCS resources, and many additional external data types from other relevant resources. The IKE resources are built on the infrastructure, analysis tools, and data that were established in the LINCS pilot phase. For the DSR component, the DCIC is managing several internal research projects and supports several external data science research projects, addressing various data integration and intracellular molecular regulatory network challenges. The CTO efforts of the DCIC have established several educational resources, including a LINCS massive online open course (MOOC) on Coursera (https://www.coursera.org/learn/bd2k-lincs), a new PhD track in Big Data Biostatistics at the University of Cincinnati, and an intensive 10-week summer research training program for graduate and undergraduate students. In addition, the DCIC is initiating and supporting diverse collaborative projects that leverage LINCS resources and disseminate LINCS data and tools. One effort central within LINCS is to standardize workflows and pipelines to ensure that they can be version controlled, sharable, and evaluated. This is achieved by publishing pipelines as Notebooks (Shen, 2014; Wang and Ma'ayan, 2016) , and containerizing pipelines using platforms such as Docker (Merkel, 2014) . The Center also aims to develop and deploy a next-generation computational infrastructure and novel analysis tools and methods that enable researchers to glean new insights from integrative models of biological systems, while linking complex diseases/phenotypes with drugs and the pathways targeted by those drugs in different cells and tissues.
LINCS Program Websites, Portals, and Databases
Sites that Cover Content from the Entire LINCS Consortium lincsproject.org: Informational Site about the LINCS Program. The entry point to access data and information about the LINCS program is http://www.lincsproject.org, a central hub for both the research community and general public. This website, along with the LINCS Data Portal (LDP), contains details about the assays, cell types, and perturbagens that are currently part of the library, as well as the LINCS DSGCs and DCIC, LINCS-related publications, news, events, video tutorials, workflows, and software that can be used for analyzing LINCS data. The LINCS mobile app, available on iTunes and Google Play, is a streamlined version of the lincsproject.org website. Cell Systems Perspective and relevant biological processes. Users can also conduct searches, for example, by cell line, small molecule, gene, or protein of interest. All data are publicly available and no account is required for access. Datasets may be added to a checkout basket to be later consolidated for a downloadable package in a compressed file containing both the data and the relevant metadata. Each LINCS dataset has its own landing page with metadata details, analysis methods, and a data level designation. Data level designations range from 1 to 4, with raw data assigned level 1, and fully processed signatures are level 4. The data level concept was adopted from The Cancer Genome Atlas project (Akbani et al., 2014) , with data level definitions adjusted and customized for data originating from different assays. Table 1 summarizes LINCS DSGC assays and datasets available on the LDP as of September 1, 2017.
DSGCs Official Center Websites
In addition to accessing LINCS data and tools through lincsproject.org and the LDP, each center has an official website providing additional center-specific information. Centers have made tools available on these sites to allow users to uniquely explore the data through web-based applications, command line interfaces, and application program interfaces (APIs). Clue.io: Platform to Interface with the L1000, P100, and GCP Data. CMAP and LINCS unified environment (CLUE), accessible at http://clue.io, is a computational environment designed to be executed on the cloud with pre-loaded gene expression profiles and perturbation datasets, analytical tools, and web applications. CLUE serves data generated, and applications developed, by the two LINCS Broad DSGCs. The aim of CLUE is to facilitate engagement with the highly dimensional L1000, P100, and GCP data by users who lack a substantial computational background. Access to this data is provided by user-friendly web-based applications, as well as command line interfaces and APIs. Free accounts are available to academic and not-for-profit users. ). Users may also access the primary mass spectrometry data in the form of Skyline documents, the standard in the field for analysis of targeted proteomics. Panorama serves as PCCSE's cloud computing infrastructure, and complete data quality control and normalization pipeline for targeted proteomics data generated by PCCSE is executed programmatically in Panorama to ensure uniform data treatment.
HMS LINCS Database: Access to Data and Tools Produced by the HMS LINCS

LINCS Tools and Workflows
The LINCS Consortium has developed software tools and analysis platforms to facilitate interaction with LINCS data, including visualization and analysis of LINCS data across LINCS data types, and in the context of other data (Table 2 ). Below we highlight some of the LINCS tools and platforms. Each of these tools and platforms may also be accessed through lincsproject.org. iLINCS: An Integrated System to Analyze LINCS and Other Data iLINCS (http://www.ilincs.org/) is a web portal aimed at providing LINCS transcriptomic and proteomic dataset analysis tools to a biologist audience. Users are guided through four pipelines: Genes, Datasets, Signatures, and Maps. The Genes pipeline allows users to input a gene set of interest, and then to select a LINCS or non-LINCS dataset and signatures to query, analyze, and visualize. The Datasets pipeline permits users to construct a signature from a selected dataset, perform functional enrichment and pathway analysis on that signature, and search for concordant (or discordant) LINCS and non-LINCS signatures. The Signatures pipeline also allows users to upload or select a signature, identify similar signatures, and analyze their common features, including the biological pathways that may underly groups of similar signatures. The Maps pipeline permits users to select a 2D map of two signature libraries, mine relationships among these signatures, and analyze the features of similar signatures. piLINCS: An Integrated System to Analyze LINCS Proteomics Data piLINCS (http://www.pilincs.org) provides both interactive and API access to the proteomics data generated by the LINCS program, including P100 and GCP profiles, which are automatically imported from Panorama. Users can filter profiles based on assay, cell type, perturbation, and dose; merge multiple profiles; download datasets in multiple formats; and send selected profiles to iLINCS for further analysis. In addition to processed The GR Browser supports analysis of dose-response data using growth rate inhibition (GR) metrics, which correct for the effects of variation in growth rate in the evaluation of drug response (Hafner et al., , 2017a (Hafner et al., , 2017b Niepel et al., 2017) . Growth ratecorrected response metrics such as GR 50 , GR max , and GR AOC are more robust and biologically informative than traditional metrics such as IC 50 and E max , and are used to evaluate drug response in the LINCS MCF10A Common Project, the MEP-HMS LINCS Joint Project, the HMS LINCS Seeding Density Project, and the Broad-HMS LINCS Joint Project datasets . GR and traditional response metrics can be visualized at the GR Calculator as scatterplots and dose-response grids sorted for drug or cell types. LINCS dose-response data can also be downloaded by users and GR tools are available as stand-alone algorithms for integration into BioConductor and other offline pipeline applications. LINCS Proteomics Data Portal LINCS Proteomics Data Portal (http://lincsproteomics.org) has been developed by DCIC in coordination with the LINCS proteomics community to facilitate exploration of LINCS proteomic data and related resources. The portal facilitates finding and downloading proteomic data, provides tailored ''datacentric'' and ''assay (or annotation)-centric'' views, and integrates tailored tools, e.g., piLINCS and piNET, to facilitate navigation, search, and interpretation of LINCS proteomics data. L1000CDS2: LINCS L1000 Characteristic Direction Signatures Search Engine L1000CDS2 (http://amp.pharm.mssm.edu/L1000CDS2/) is a search engine that returns LINCS L1000 drug perturbation signatures that either mimic or reverse a user-input signature of gene symbols . The search is completed against a subset of the L1000 data in which the differentially expressed genes were calculated using the characteristic direction method (Clark et al., 2014 
Other Tools
Other tools and interfaces that have been developed by the consortium or customized for LINCS data include OMICSIntegrator (http://fraenkel-nsf.csbi.mit.edu/omicsintegrator/), which can be used to identify putative molecular pathways underlying integrated omics data (Tuncbag et al., 2016) ; Enrichr (http://amp. pharm.mssm.edu/Enrichr), which is a search engine for gene sets (Chen et al., 2013; Kuleshov et al., 2016) ; and Harmonizome (http://amp.pharm.mssm.edu/Harmonizome/), a database that serves integrative omics data from 66 resources, including LINCS . Slicr (http://amp.pharm.mssm. edu/Slicr), is a signature store for L1000 signatures, whereas LINCS Canvas Browser (http://www.maayanlab.net/LINCS/ LCB/) visualizes L1000 on canvases that cluster signatures based on their expression vector similarity . Additional LINCS-specific tools include SEP-L1000 (http:// maayanlab.net/SEP-L1000), an interface for predictions of side effects for >20,000 LINCS-profiled small molecules (Wang et al., 2016a) ; Panorama, a web-based platform for storing, sharing, and analyzing proteomics data (Sharma et al., 2014) analyzed by Skyline (MacLean et al., 2010), a Windows-based client commonly used for processing data from proteomics experiments; and the Open Microscopy Environment (OMERO), an image data management platform that allows users to view, organize, analyze, and share imaging data securely with collaborators using a variety of different permission levels (Allan et al., 2012) . The OMERO platform has been adopted by the LINCS Consortium to manage the images that are collected at various DSGCs; and several members of the consortium are working on developing a Microscopy Imaging Commons, an open environment to store and share microscopy images.
growth factors and other ligands, cells, and some elements of experimental metadata, are standardized across all LINCS DSGCs. Harmonization of these annotations facilitates data analysis, data formatting, and data visualization strategies being used by the LINCS community. The standardized metadata is also important for the development of databases and data repositories that store and share LINCS data. Led by the DCIC, and in collaboration with the Center for Expanded Data Annotation and Retrieval (CEDAR) (Musen et al., 2015) , the consortium is developing automated mechanisms to capture metadata when it is produced through customized web forms. (Taylor et al., 2008) , and NCBI PubChem (Bolton et al., 2008) .
Data Processing and Analysis Pipelines
In an effort to make the process of generating LINCS data completely transparent, DCIC is leading an effort in validating, documenting, and releasing all computational processing pipelines used by DSGSs to process and analyze LINCS data. Two main objectives of the effort are to (1) facilitate de novo reconstruction of computational pipelines by completely describing all processing steps; and (2) facilitate the re-use of computational pipelines developed and used by DSGCs. To facilitate de novo reconstruction, DCIC is leading an effort to provide assay-specific standards for documenting all details of data processing and analysis. To facilitate the re-use of existing pipelines, DCIC works closely with DSGCs to test and validate all computational pipelines. Whenever possible, DCIC is also creating and releasing ready-to-use Docker containers implementing individual processing and analysis pipelines.
Data Availability
In general, all LINCS data are available to all, pre-publication, with no restrictions. The only exception is the raw RNA-seq data collected from patients, which will be made available for download from dbGAP to adhere to patient privacy protocols. Some websites developed by the data-generation centers, such as Clue.io, which is hosting the L1000 data and related tools, the DToxS data portal, or Synapse, which is hosting the MEP LINCS data and tools, require login and an account. However, versions of the data are made openly available by the DCIC, and through public repositories such as GEO. The LINCS Consortium established a data release policy which is available at: http://lincsproject.org/LINCS/data/release-policy. The MCF10A Common Project As the biomedical research community is greatly concerned with the reproducibility of molecular and cell biology studies (Begley, 2013) , the LINCS investigators jointly work on cross-center projects. The consortium is currently working toward identifying the molecular networks that determine how MCF10A cells receive and integrate external signals in ways that influence MCF10A physiology, such as proliferation, differentiation, and motility. This is a dynamic process that can best be approached by integrating information from the unique assays, which are conducted by several LINCS DSGCs. It is likely that responses involve transcriptional and proteomic network reconfigurations in the first few hours, followed by epigenomic changes that are induced in hours to days. The consortium has decided to test responses of eight diverse drugs (those that are known to target different canonical pathways) and apply these in different concentrations while measuring cell viability, mRNA levels, protein levels, epigenetic markers, and cell morphology under different concentrations and time points. Understanding the extent of agreement among these assays in perturbing canonical pathways will allow the consortium to evaluate the extent to which the assays and data across centers allows for reproducible and cohesive findings.
Conclusions
The six LINCS DSGCs are producing unique datasets and resources using state-of-the-art high-throughput transcriptomics, proteomics, epigenomics, biochemical assays, and imaging data. These data are collected by the unique assays such as L1000 and RNA-seq for the transcriptomics; P100, GCP, RPPA, microwestern, and other expression proteomics techniques; and MEP, CycIF, and other methods for cell phenotypic and morphological imaging. These data are organized, analyzed, visualized, and integrated jointly by the DSGCs and the DCIC, who actively develop metadata standards, tools, and portals ( Figure 2 ). Along these lines the LINCS Consortium is centrally involved in making LINCS datasets and tools adhere to the FAIR principles (Wilkinson et al., 2016) . The consortium is working on developing specific evaluations for LINCS datasets and tools so those are maximally FAIR. The overall aim of LINCS is to produce a long-term resource that will assist individual investigators to form novel hypotheses about the inner workings of human cells and tissues in normal physiology and in disease.
